Set A | Set B | Set C | |||||
---|---|---|---|---|---|---|---|
Antibody and target | No predose | 1.0 mg/1 d | No predose | 0.25 mg/1 d | No predose | 0.25 mg/1 h | 1.0 mg/1 h |
111In-veltuzumab IgG | |||||||
Tumor | 16.9 ± 4.1 | 9.0 ± 1.4 | 22.5 ± 3.8 | 16.8 ± 2.0 | 22.1 ± 2.7 | 18.1 ± 2.5 | 13.2 ± 4.5 |
Tumor weight | 0.532 ± 0.124 | 0.677 ± 0.302 | 0.264 ± 0.081 | 0.255 ± 0.047 | 0.307 ± 0.150 | 0.323 ± 0.144 | 0.352 ± 0.258 |
Liver | 3.5 ± 0.6 | 4.0 ± 0.5 | 4.7 ± 1.7 | 5.6 ± 0.4 | 4.1 ± 0.4 | 4.7 ± 1.3 | 4.7 ± 0.3 |
Spleen | 4.3 ± 1.8 | 4.3 ± 0.5 | 5.4 ± 4.0 | 5.6 ± 0.8 | 3.6 ± 0.8 | 4.1 ± 1.0 | 4.3 ± 0.5 |
Kidneys | 5.0 ± 0.7 | 7.1 ± 1.0 | 4.8 ± 0.5 | 5.40 ± 0.8 | 5.2 ± 0.6 | 6.7 ± 1.2 | 6.6 ± 0.3 |
Lungs | 6.9 ± 1.5 | 7.8 ± 1.0 | 5.9 ± 1.0 | 7.2 ± 1.5 | 6.0 ± 2.4 | 6.0 ± 1.0 | 7.7 ± 2.9 |
Blood | 14.8 ± 2.0 | 20.3 ± 2.6 | 16.1 ± 2.3 | 22.6 ± 2.3 | 15.2 ± 1.9 | 18.2 ± 2.8 | 19.8 ± 2.2 |
TF4-pretargeted 111In-IMP-288 | |||||||
Tumor | 11.28 ± 0.21* | 2.96 ± 0.75* | 13.40 ± 0.60 | 6.82 ± 0.75* | 13.23 ± 1.81 | 6.74 ± 1.51 | 2.40 ± 0.61 |
Tumor weight | 0.559 ± 0.209 | 0.754 ± 0.253 | 0.303 ± 0.061 | 0.469 ± 0.180 | 0.228 ± 0.067 | 0.329 ± 0.131 | 0.195 ± 0.063 |
Liver | 0.43 ± 0.12 | 0.68 ± 0.17 | 0.63 ± 0.10 | 0.71 ± 0.17 | 0.66 ± 0.30 | 0.81 ± 0.14 | 0.77 ± 0.25 |
Spleen | 0.63 ± 0.23 | 1.38 ± 0.52 | 1.40 ± 0.71 | 1.40 ± 0.56 | 1.32 ± 0.98 | 1.29 ± 0.69 | 1.23 ± 0.51 |
Kidneys | 1.14 ± 0.14 | 1.50 ± 0.09 | 1.38 ± 0.18 | 1.31 ± 0.26 | 1.53 ± 0.27 | 1.46 ± 0.24 | 1.27 ± 0.15 |
Lungs | 0.37 ± 0.03 | 0.68 ± 0.39 | 0.34 ± 0.06 | 0.42 ± 0.09 | 0.48 ± 0.14 | 0.38 ± 0.04 | 0.50 ± 0.22 |
Blood | 0.01 ± 0.00 | 0.02 ± 0.01 | 0.02 ± 0.00 | 0.02 ± 0.01 | 0.02 ± 0.01 | 0.02 ± 0.00 | 0.02 ± 0.01 |
Animals were necropsied either 3 d after 111In-veltuzumab injection or 24 h after 111In-IMP-288 injection (111In-IMP-288 was administered 29.5 h after TF4). %ID/g for each groups is shown (mean ± SD; n = 5/group, except where indicated by *, where n = 4).